From: Emerging role of lipid metabolism alterations in Cancer stem cells
Metabolism type | Drug | Targeting enzyme | Cancer type | Stage |
---|---|---|---|---|
Lipogenesis | Resveratrol | FASN | Breast cancer CSCs [104, 209]. Pancreatic CSCs [232] | Clinical Trial |
Cerulenin | FASN | Pre-clinical | ||
Orlistat | FASN | NSCLC [203] | FDA-approved anti-obesity drug | |
Lipid uptake | CD36 antibody | CD36 | OSCC [126] | Pre-clinical |
MTN | CD36 | Glioblastoma CSCs [125] | Pre-clinical | |
FAO | Etomoxir | CPT1A | Pre-clinical | |
ST1326 | CPT1A | Pre-clinical | ||
Lipid desaturation | SSI-4 | SCD1 | Liver CSCs [176], | Pre-clinical |
BetA | SCD1 | CRC [184] | Pre-clinical | |
PluriSin#1 | SCD1 | Teratomas [148] | ||
MF-438 | SCD1 | Lung cancer CSCs [177] | Pre-clinical | |
A939572 | SCD1 | Pre-clinical | ||
Cay10566 | SCD1 | Breast Carcinoma [216] | Pre-clinical | |
T-3764518 | SCD1 | CRC [234] | Pre-clinical |